5CVCureVac N.V.
Delisted—Mkt Cap: —P/E: —267d ago
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for vario…
Industry Peers
Biotechnology$133.74BUSDP/E 30.8
$78.76BUSD
$77.45BUSDP/E 18.6
$60.46BUSDP/E 37.0
$57.09BUSDP/E 36.6
$44.04BUSDP/E 18.8
$43.24BUSD
$41.52BUSDP/E 65.7
$34.17BUSDP/E 44.6
$33.73BUSDP/E 31.4
$26.71BUSD
$25.70BUSD
$25.30BUSDP/E 15.9
$24.89BUSD
$21.74BUSDP/E 28.1
$20.62BUSDP/E 27.7
$15.47BUSDP/E 16.3
$15.13BUSDP/E 18.1
$14.46BUSDP/E 18.4
$13.02BUSD
Key Statistics
Company
Market Cap—
Enterprise Value351.33M $
Revenue (TTM)76.89M $
Gross Profit71.73M $
Net Income (TTM)140.03M $
Revenue/Share0.4783 USD
Last Price—
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees825
CountryDE
SectorHealthcare
IndustryBiotechnology
ISINNL0015436031
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA1.67
EV/Revenue4.57
P/S12.59
P/B0.81
EPS (TTM)0.57
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin93.29%
Oper. Margin573.04%
EBITDA Margin273.81%
Profit Margin182.11%
ROE—
ROA—
Growth
Revenue Growth-89.00%
Earnings Growth24.00%
Cash Flow & Leverage
Operating CF-130.58M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-414.16M $
Net Debt/EBITDA-1.97
Balance Sheet
Debt/Equity4.03
Current Ratio3.70
Quick Ratio1.88
Book Value/Sh4.815 EUR
Cash/Share2.300 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.225.17M
Float180.77M
Insiders0.10%
Institutions10.43%
Technical
SMA 504.260 EUR
SMA 2004.178 EUR
Beta1.81
S&P 52W Chg20.73%
Avg Vol (30d)—
Avg Vol (10d)151.30K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—